Company Description
Day One Biopharmaceuticals, Inc., a commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States.
The company’s lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory low-grade glioma; and Ipsen, a frontline raf-altered pLGG which is in Phase III clinical trial stage.
It also developing DAY301, which is in phase I clinical trial for adult and pediatric cancers; and VRK1 Inhibitor which is in pre-clinical stage for adult and pediatric cancers.
Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.
| Country | United States |
| Founded | 2018 |
| IPO Date | May 27, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 181 |
| CEO | Jeremy Bender |
Contact Details
Address: 1800 Sierra Point Parkway, Suite 200 Brisbane, California 94005 United States | |
| Phone | 650 484 0899 |
| Website | dayonebio.com |
Stock Details
| Ticker Symbol | DAWN |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001845337 |
| CUSIP Number | 23954D109 |
| ISIN Number | US23954D1090 |
| Employer ID | 83-2415215 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jeremy Bender M.B.A., Ph.D. | Chief Executive Officer, President and Director |
| Charles N. York II, M.B.A. | Chief Operating Officer and Chief Financial Officer |
| Adam Dubow J.D. | General Counsel, Chief Compliance Officer and Secretary |
| John Stubenrauch Ph.D. | Chief Technology Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 18, 2025 | 144 | Filing |
| Aug 14, 2025 | SCHEDULE 13G/A | Filing |
| Aug 6, 2025 | SCHEDULE 13G/A | Filing |
| Aug 5, 2025 | 10-Q | Quarterly Report |
| Aug 5, 2025 | 8-K | Current Report |
| Jul 17, 2025 | SCHEDULE 13G | Filing |
| Jun 3, 2025 | 8-K | Current Report |
| May 16, 2025 | 144 | Filing |
| May 16, 2025 | 144 | Filing |
| May 16, 2025 | 144 | Filing |